December 8, 2021 Non Regulatory Promore Pharma granted US patent regarding treatment of chronic wounds
November 19, 2021 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021
November 16, 2021 Regulatory Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma
November 9, 2021 Regulatory Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
October 25, 2021 Regulatory Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
September 13, 2021 Regulatory Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia
August 17, 2021 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021
July 20, 2021 Regulatory The rights issue is registered and the trading in Paid Subscription Shares ceases
May 27, 2021 Regulatory Promore Pharma informs about the last day of trading to receive subscription rights
May 27, 2021 Regulatory Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021
May 27, 2021 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021
May 26, 2021 Non Regulatory Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna
May 7, 2021 Regulatory Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy
April 28, 2021 Regulatory Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia
February 16, 2021 Non Regulatory Invitation to Presentation of Promore Pharma’s Year-end report for 2020